PEAK6 Investments LLC Makes New $956,000 Investment in Bio-Rad Laboratories, Inc. (NYSE:BIO)

PEAK6 Investments LLC bought a new stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 2,857 shares of the medical research company's stock, valued at approximately $956,000.

Other institutional investors have also added to or reduced their stakes in the company. Capital Advisors Ltd. LLC grew its position in Bio-Rad Laboratories by 193.8% in the 2nd quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company's stock valued at $26,000 after purchasing an additional 62 shares during the period. UMB Bank n.a. increased its position in shares of Bio-Rad Laboratories by 140.6% during the third quarter. UMB Bank n.a. now owns 77 shares of the medical research company's stock worth $26,000 after acquiring an additional 45 shares in the last quarter. Gladius Capital Management LP acquired a new stake in shares of Bio-Rad Laboratories in the 3rd quarter worth about $32,000. Headlands Technologies LLC bought a new position in Bio-Rad Laboratories in the 2nd quarter valued at about $51,000. Finally, Quarry LP bought a new stake in Bio-Rad Laboratories during the 2nd quarter worth approximately $59,000. 65.24% of the stock is owned by institutional investors and hedge funds.

Bio-Rad Laboratories Stock Performance

NYSE:BIO traded down $6.49 during trading hours on Tuesday, reaching $332.28. The stock had a trading volume of 112,327 shares, compared to its average volume of 182,946. Bio-Rad Laboratories, Inc. has a 12-month low of $262.12 and a 12-month high of $387.99. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.52 and a current ratio of 6.14. The stock has a 50 day simple moving average of $341.01 and a 200 day simple moving average of $318.35.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last released its quarterly earnings data on Wednesday, October 30th. The medical research company reported $2.01 EPS for the quarter, beating the consensus estimate of $1.16 by $0.85. The business had revenue of $649.70 million for the quarter, compared to the consensus estimate of $628.18 million. Bio-Rad Laboratories had a negative net margin of 30.18% and a positive return on equity of 3.74%. The company's revenue was up 2.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.33 earnings per share. Sell-side analysts forecast that Bio-Rad Laboratories, Inc. will post 10.29 earnings per share for the current year.

Insider Transactions at Bio-Rad Laboratories

In other news, EVP James Barry sold 623 shares of the company's stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total value of $205,895.27. Following the completion of the transaction, the executive vice president now directly owns 147 shares in the company, valued at approximately $48,582.03. This represents a 80.91 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Andrew J. Last sold 3,000 shares of the stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $329.94, for a total transaction of $989,820.00. Following the transaction, the chief operating officer now owns 7,559 shares in the company, valued at $2,494,016.46. The trade was a 28.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 17.50% of the company's stock.

Analysts Set New Price Targets

BIO has been the topic of a number of recent research reports. StockNews.com upgraded Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a report on Friday, November 1st. Royal Bank of Canada lifted their price objective on shares of Bio-Rad Laboratories from $446.00 to $469.00 and gave the stock an "outperform" rating in a report on Thursday, October 31st. Wells Fargo & Company initiated coverage on shares of Bio-Rad Laboratories in a report on Tuesday, August 27th. They issued an "equal weight" rating and a $340.00 target price for the company. Finally, Citigroup upped their price objective on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a "buy" rating in a research report on Thursday, October 31st. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $391.80.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.